Blinatumomab

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research results on blinatumomab presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Blinatumomab extended survival when combined with chemotherapy for adults with minimal residual disease-negative, B-lineage acute lymphoblastic leukemia, according to a study presented at ASH Annual Meeting and Exposition.

Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.

In this video, Lori Muffly, MD, MS, discussed a debate session that focused on the sequencing and importance of CD19-targeting therapies from the Society of Hematologic Oncology Annual Meeting.

In this video, Lori Muffly, MD, MS, discussed a presentation from the Society of Hematologic Oncology Annual Meeting about the how the use of hyper-CVAD for acute lymphoblastic leukemia has evolved over time.

Ponatinib and blinatumomab induced high rates of complete molecular remission among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to research presented during the virtual ASCO Annual Meeting.

Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy improved outcomes for children and young adults with high-risk first relapse of B-cell acute lymphoblastic leukemia.

Young patients with B-cell acute lymphoblastic leukemia had shorter RFS and EFS if they received blinatumomab before chimeric antigen receptor T-cell therapy, according to results presented at the virtual ASH Annual Meeting and Exposition.

A chemotherapy-free first-line treatment strategy led to high rates of molecular response and survival among a subset of adults with acute lymphoblastic leukemia, according to study results published in The New England Journal of Medicine.

ORLANDO — In this video, Thomas Alexander, MD, pediatric oncologist and hematologist at the University of North Carolina, discusses a late breaking abstract presented at the ASH Annual Meeting and Exposition.